The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...

New passenger car registrations in Croatia declined by 3.4% on the year in the first two months of 2025, to 8,717, the ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front ...

while Europol dismantled a multimillion euro hearing aid scam in France. Sanofi will acquire Dren Bio's immunology unit, advancing its autoimmune treatment capabilities into prospective growth areas.

Sanofi is acquiring private biotech, Dren Bio’s targeted bispecific myeloid cell engager (MCE), DR-0201 for an upfront payment of $600 million. In clinical studies, DR-0201 has shown robust B ...

Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies, from Dren Bio Inc. for $600 ...